Treatment Patterns and Clinical Outcomes for Patients Living with Active Giant Cell Arteritis in Canada

The current 1-year TCZ treatment limit in Canada may be inadequate for long-term disease control. Adverse events were generally low, though hypertension, hyperglycemia, and infections were common. Two bowel perforations occurred in the TCZ group. These findings underscore the need for individualized, long-term treatment in GCA to minimize steroid exposure and maintain disease control. Future research should explore optimal therapy durations and support policy changes to expand access to steroid-sparing agents to improve long-term GCA outcomes.